DDInter1141 DDInter782
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Megestrol acetate {u} (Compound) resembles {v} (Compound) Dydrogesterone
Megestrol acetate {u} (Compound) resembles {v} (Compound) Methyltestosterone
Megestrol acetate {u} (Compound) binds {v} (Gene) PGR
Megestrol acetate {u} (Compound) palliates {v} (Disease) breast cancer
Megestrol acetate {u} (Compound) is included by {v} (Pharmacologic Class) Progesterone Congeners
Megestrol acetate (Compound) resembles Dydrogesterone (Compound)
Megestrol acetate (Compound) resembles Methyltestosterone (Compound)
Megestrol acetate (Compound) binds PGR (Gene)
Megestrol acetate (Compound) palliates breast cancer (Disease)
Megestrol acetate (Compound) is included by Progesterone Congeners (Pharmacologic Class)